BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 26, 2026
Home » Topics » Medical technology, Financings

Medical technology, Financings
Medical technology, Financings RSS Feed RSS

International currency symbols

Wandercraft lines up $45M for exoskeleton technology

Jan. 21, 2022
By Catherine Longworth
Exoskeleton company Wandercraft SAS has landed $45 million in a series C round led by U.S. fund Quadrant Management. The company’s first commercial exoskeleton, Atalante, received CE marking in 2019 and has sold for around $176,000 a piece to European rehabilitation hospitals offering gait re-learning treatment.
Read More

Financings for Jan. 21, 2022

Jan. 21, 2022
Med-tech firms raising money in public or private financings, including: Casana, Nanalysis.
Read More
Hand holding dollar sign

Oxford University spin-off secures $75M series B for nanoimaging technology

Jan. 20, 2022
By Catherine Longworth
Investors have backed Oxford University spin-off ONI Ltd. with $75 million to push commercialization of its nanoimaging technology. The startup’s flagship product Nanoimager is a desktop, super resolution microscope capable of visualizing, tracking, and imaging individual molecules in living cells with 20 nm resolution. The technology is already in use with biomedical companies to aid development of more efficient, targeted therapies.
Read More

Financings for Jan. 20, 2022

Jan. 20, 2022
Med-tech firms raising money in public or private financings, including: Polyphotonix, Theromics, Wandercraft.
Read More
Hand holding gear, dollar sign

Med-tech IPOs, VC rounds hit records in 2021; overall financings down 17%

Jan. 19, 2022
By Karen Carey
While med-tech financings in 2021 fell about 17% below the amount raised in 2020, the industry still collected $49.26 billion, significantly more than each of the two previous years, and driven primarily by digital health and diagnostic technologies.
Read More

Financings for Jan. 19, 2022

Jan. 19, 2022
Med-tech firms raising money in public or private financings, including: Amber Implants, Iterative Scopes.
Read More
Healshape's breast bioprosthesis being 3D printed

Healshape developing 3D-printed breast bioprosthesis using patients’ own cells

Jan. 18, 2022
By Bernard Banga
PARIS – Healshape SAS is preparing a $6.8 million series A round to develop a 3D bioprinted breast implant obtained from the patients' own cells. Supported by Pulsalys SAS, Lyon Saint-Etienne’s technology transfer acceleration company, this startup from Villeurbanne, France, has already benefited from more than a million dollars of French public funding and subsidies.
Read More

Financings for Jan. 18, 2022

Jan. 18, 2022
Med-tech firms raising money in public or private financings, including: Avinger, Hyivy.
Read More

Financings for Jan. 14, 2022

Jan. 14, 2022
Med-tech firms raising money in public or private financings, including: Bausch + Lomb.
Read More
SPAC ticker illustration

Viveon and Suneva combine to form $511M aesthetics business

Jan. 13, 2022
By Catherine Longworth
Viveon Health Acquisition Corp. (VHAQ) reported a merger deal with regenerative aesthetics company Suneva Medical Inc. According to the terms of the deal, the special purpose acquisition company (SPAC), will issue 25 million shares and up to 12 million earnout shares to Suneva shareholders. The pro forma equity valuation of the companies is expected to be approximately $511 million, with the merger slated for completion in the first half of 2022.
Read More
Previous 1 2 … 147 148 149 150 151 152 153 154 155 … 254 255 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing